SphingoTec announces the successful closing of a Series C financing round. The raised capital will allow the company to reach profitability through sustained and strategic commercialization of its…
SphingoTec introduced together with Boditech Med Inc. (Boditech) at the 42nd AKI & CRRT Course in Vicenza the innovative kidney function biomarker penKid developed by SphingoTec and licensed to…
SphingoTec has established an extended intellectual property portfolio covering markers for acute care conditions such as sepsis, acute heart failure and acute kidney injury.
With the mission of improving patient management in critical care settings, SphingoTec has started a series of collaboration with internationally leading academic and non-academic medical centers.
Next to our Nexus IB10 automated and portable immunoassay system we also provide customized MTP assays and testing services to fulfill the specific requirements of our customers.
Proenkephalin A 119–159 (penKid) as a Promising New Biomarker Candidate for Early Detection of Delayed Graft Function After Kidney Transplantation
Join Dr. Christian Nußhag for a webinar where he…
Role of Proenkephalin in Assessing Recovery from AKI and AKI-D
Discover new diagnostic insights presented by Dr. Christian Nusshag at the 29th AKI & CRRT in San Diego. During his presentation on…
Overcoming the Limitations of Acute Kidney Injury (AKI) Diagnostics in the Emergency Department: the Biomarker Proenkephalin for Early Recognition of AKI
Acute Kidney Injury is a serious…
Sepsis in the Emergency Department: Recognizing High-Risk Patients With the Biomarker Bioactive Adrenomedullin
Recognizing the high risk sepsis patients at the Emergency Department (ED) poses a…
